Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Munich – page 68

1 191 clinical trials in Munich, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Munich at a glance
1 191
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

1 191 trials in Munich

Open in trial search

Study of FNP-223 tablets to slow disease progression in patients with Progressive Supranuclear Palsy (PSP)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt
  • Sponsor:Ferrer Internacional S.A.

Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on Long-Term Safety and Effectiveness of Treprostinil Palmitil for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Study of Chemotherapy with Osimertinib in Non-Small Cell Lung Cancer Patients Who Have Progressed After Initial Osimertinib Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Study on Long-Term Safety and Effects of Pegcetacoplan for Patients with Geographic Atrophy from Age-Related Macular Degeneration

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Study of Copanlisib with Rituximab and CHOP for Untreated Diffuse Large B-Cell Lymphoma in Patients Aged 18-80

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Study on MB-CART19.1 for Patients with Relapsed or Refractory CD19 Positive B Cell Malignancies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
  • Sponsor:Miltenyi Biomedicine GmbH

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Bi 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Acromegaly

Not recruiting

Study on the Effects of Paltusotine for Patients with Untreated Acromegaly

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Munich

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on various cancer types, including metastatic prostate cancer, colorectal cancer, and bladder cancer. Novel therapeutic approaches combining immunotherapy with established treatments are being investigated.

  • Prostate Cancer Treatment Innovations
  • Colorectal Cancer Therapies
  • Early-Stage Bladder Cancer Management

Research aims to improve survival rates and treatment effectiveness through targeted therapies and immunological approaches.

02 Cardiovascular and Hematological Studies

Important research in heart disease and blood conditions, including studies on TTR amyloidosis and prevention of thrombotic events. Novel medications are being tested to improve patient outcomes.

  • Cardiac Amyloidosis Treatment
  • Thrombosis Prevention
  • Cardiovascular Disease Management

Focus on developing innovative treatments for complex cardiovascular conditions and preventing blood clots.

03 Neurology and Mental Health

Advanced research into neurological conditions, particularly focusing on Alzheimer's disease and autoimmune dementia. Studies aim to develop new therapeutic approaches and improve diagnostic tools.

  • Early-Stage Alzheimer's Treatment
  • Autoimmune Dementia Therapy
  • Cognitive Function Studies

Innovative approaches to treating and managing neurodegenerative conditions.

04 Immunology and Infectious Diseases

Critical research in HIV prevention and immune system modulation, including studies on transplant medicine and vaccine development for yellow fever.

  • HIV Pre-Exposure Prophylaxis
  • Transplant Immunology
  • Vaccine Development

Focus on preventing infectious diseases and improving transplant outcomes through immunological interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.